| Revenue growth | FY26 revenue ₹66.9cr; H2 revenue up 23% YoY to ₹41.63cr. |
|---|---|
| Margins | Gross margins improved 54% to 59%; H2 EBITDA margin at 26.3%. |
| Demand visibility | Strong recurring revenue at 93% of business; doctor base grew to 6300+. |
| Management confidence | High; aiming for 30% CAGR and Main Board listing within 3 years. |
Growth
FY26 revenue grew 8.6% YoY to ₹66.9cr; PAT increased to ₹6.6cr from ₹6cr. H2 revenue surged 64.4% sequentially.
Outlook
Targeting 30% CAGR and main board listing in 3 years. Launching Xelix clinic platform to reach 50 clinics.
Risks
Business seasonality (H1/H2 split), regulatory delays in product licensing, and high working capital requirements for inventory maintenance.
Earnings Call filed with NSE, NSE: AAKAAR. Summary written with AI assistance from the document.
Aakaar Medical Technologies Ltd: key numbers
- Share price
- ₹66.00
- Market cap
- ₹93.54 Cr
- Revenue (annual)
- ₹66.96 Cr
- Net profit (annual)
- ₹6.64 Cr
- P/E (TTM)
- 14.1×Sector 53.1×
- Promoter holding
- 67.05%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aakaar Medical Technologies Ltd
All →Aakaar Medical Technologies Business Update
Aakaar Medical Technologies provided an operational update for Q1 FY2026-27, detailing expansion in its clinic network, distributor count, and overall sales force effectiveness.
Aakaar Medical Technologies Legal & Regulatory
Aakaar Medical Technologies addressed an NSE notice regarding Regulation 44(3) non-compliance, stating the lapse was inadvertent and that corrective measures have been implemented.
Aakaar Medical Technologies Legal & Regulatory
Aakaar Medical Technologies submitted a share‑capital audit reconciliation reporting issued capital of ₹14.17 Crore. The filing satisfies SEBI (Depositories and Participants) Regulation 76 requirements.
- Value
- ₹14.17 Cr
Aakaar Medical Technologies Management Change
Aakaar Medical Technologies appointed NAM & ASSOCIATES as Secretarial Auditor for a five-year term. The firm brings extensive experience in corporate and foreign exchange laws.
- Execution
- 60 months
Aakaar Medical Technologies Annual General Meeting
Aakaar Medical Technologies held its 13th AGM on June 30, 2026. Key outcomes include financial approval and increasing authorized share capital.
Aakaar Medical Technologies Earnings Call: Key Takeaways
Aakaar Medical Technologies reported FY26 revenue of INR 67 Cr (up 8.6%) and PAT of INR 6.63 Cr (up 10%). The company is shifting towards an asset-light DODO clinic model via its Xelix platform.